To celebrate our golden anniversary, we commissioned a group of innovative and provocative commentaries looking 50 years into the future. When we invited writers to contribute we encouraged them to hypothesise and conceptualise, challenging them to embrace ‘blue sky, left field, out of the box thinking’! The articles were then peer reviewed and are now part of this special edition.
|Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years? Bo Ahrén||The erosion of physical activity in Western societies: an economic death march Frank Booth and John Hawley||50 years forward: beta cells Philippe Halban||Hepatokines: unlocking the multi-organ network in metabolic diseases Alison Iroz, Jean-Pierre Couty and Catherine Postic|
|Medications for type 2 diabetes: how will we be treating patients in 50 years? Steven E. Kahn and John B. Buse||Genomic medicine at the heart of diabetes management Mark I. McCarthy||Incretin-based therapies: where will we be 50 years from now? Juris J. Meier, Michael A. Nauck||Future of muscle research in diabetes: a look into the crystal ball Michael Roden|
|50 years forward: mechanisms of hyperglycaemia-driven diabetic complications Nicholas D. F. Russell, Mark E. Cooper||Vascular AGE-ing by methylglyoxal: the past, the present and the future Casper G. Schalkwijk||The future of brown adipose tissues in the treatment of type 2 diabetes Patrick Schrauwen, Wouter D. van Marken Lichtenbelt, Bruce M. Spiegelman||Comparative genomics: beyond the horizon of the next research grant Frans Schuit|